Abstract
Pirinixil (BR 931), a new hypolipidemic agent, which has been reported to increase high density lipoprotein cholesterol levels in experimental animals was fed for 21 days (0.05% in the diet) to Wistar rats on a semi-sy n thetic diet. Pirinixil increased plasma cholesterol levels significantly without affecting plasma triglycerides. Liver cholesterol and triglycerides were markedly reduced by treatment, while combined plasma and liver lipid levels decreased approximately 20%. Liver HMG-CoA reductase activity was not affected, but cholesterol 7α-hydroxylase was significantly reduced, thus confirming data with other hypolipidemic agents in rats. The experimental findings do not support the recent hypothesis that hypolipidemic agents may increase total body lipid levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
